MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viatris Inc. - Common Stock (NQ:VTRS)

10.69 +0.05 (+0.47%)
Streaming Delayed Price Updated: 1:00 PM EST, Nov 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viatris Inc. - Common Stock

< Previous 1 2
...
14 15 16 17 18 19 20 21 Next >
News headline image
This Company Reports Its Consumer Therapeutics Could Be A Game Changer For People With Skin Problems ↗
From allergies and insect bites to sunburns and irritations, the human skin can succumb to several conditions, including acne, psoriasis, blisters, hives, actinic keratosis, rosacea, and carbuncle. 
Via Benzinga
News headline image
Viatris: Q2 Earnings Insights ↗
  Viatris (NASDAQ:VTRS) reported its Q2 earnings results on Monday, August 8, 2022 at 06:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Recession Investing: 5 High Yield Dividend Stocks For A Downturn ↗
As the healthcare industry absorbed enormous amounts of profits during the Covid-19 pandemic, many healthcare companies will be increasing shareholder distributions to entice investors to buy their... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Expert Ratings for Viatris ↗
Analysts have provided the following ratings for Viatris (NASDAQ:VTRS) within the last quarter: 
Via Benzinga
News headline image
Viatris Posts Q1 Profit Despite 5% Dip In Sales, Reiterates FY22 Guidance Above Consensus ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 8, 2022 ↗
Companies Reporting Before The Bell • Pyxis Tankers (NASDAQ:PXS) is likely to report earnings for its second quarter. 
Via Benzinga
News headline image
Recap: Viatris Q1 Earnings ↗
Viatris (NASDAQ:VTRS) reported its Q1 earnings results on Monday, May 9, 2022 at 06:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Viatris' Mylan Recalls One Batch Of Insulin Glargine Due To Missing Label ↗
Mylan Pharmaceuticals Inc, a Viatris Inc (NASDAQ: VTRS) company, is  
Via Benzinga
News headline image
7 High-Quality Dividend Stocks With High Yields ↗
These are the best dividend stocks with high yields to invest in now. BIP, EPR, FL, KMI, KHC, VTRS, and WBA can make great investments. 
Via InvestorPlace
News headline image
Looking Into Viatris's Return On Capital Employed ↗
According to Benzinga Pro, during Q1, Viatris (NASDAQ:VTRS) earned $399.20 million, a 251.33% increase from the preceding quarter. Viatris's sales decreased to $4.19 billion, a 3.45% change since Q4. 
Via Benzinga
Revolutionary Heart Therapy Offers Hope to Patients and Investors Alike
Palm Beach, FL – May 31, 2022 – FinancialNewsMedia.com News Commentary – Diabetes is a chronic health condition that occurs when your body’s blood glucose, also called blood sugar, is too high. Blood... 
Via FinancialNewsMedia
News headline image
Current Report: Viatris ↗
Viatris Inc’s price per share was $11.68 as of yesterday's market close. One year ago its price was $15.59. 
Via Talk Markets
News headline image
High Dividend 50: Viatris ↗
Viatris is currently offering an above-average dividend yield of 4.4%. The company has posted GAAP losses in each of the last two years but its payout ratio is only 13% using adjusted EPS. 
Via Talk Markets
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2022 ↗
Upgrades 
Via Benzinga
News headline image
3 Top S&P 500 Stock Market Gainers Today ↗
Hard-hit stocks led S&P 500 winners. Commodity stocks were the big losers. 
Via Investor's Business Daily
News headline image
27 Recession-Resistant Stocks To Look At Now ↗
When we enter a period of economic uncertainty, the phrase "recession-proof stocks" is tossed about, but really the only certainty is that recession-proof stocks do not... 
Via Benzinga
News headline image
Earnings Scheduled For May 9, 2022 ↗
Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million. 
Via Benzinga
News headline image
Pfizer: What Comes After the Covid-19 Fire? ↗
Success with Pfizer's Covid-19 vaccine maintains the PFE stock status as a dividend aristocrat, but don't expect miracles. 
Via InvestorPlace
News headline image
The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal 
Via Benzinga
News headline image
Biogen’s Aduhelm Crashes the Biotech Sector ↗
Aduhelm's quick approval and high price have set off pushback on the whole FDA and Medicare drug process which is not good for BIIB stock. 
Via InvestorPlace
News headline image
The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight ↗
Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that... 
Via Benzinga
News headline image
7 Cheap Stocks to Buy Now if You Have $100 to Spend ↗
The S&P 500 is off to a forgettable start this year, but that creates multiple buying opportunities if you're looking for cheap stocks. 
Via InvestorPlace
News headline image
35 Generic Drugmakers Sign To Manufacture Low-Cost Version Of Pfizer's COVID Pill ↗
 
Via Benzinga
News headline image
7 Drug Stocks to Consider After the Viatris Plunge ↗
As Viatris and other generic drug makers plunge, what should you buy instead? Consider these seven well-known drug stocks, all of which are good value in what's still a pricey market. 
Via InvestorPlace
News headline image
AbbVie, Alvotech Resolve US Patent Dispute Related To Humira Biosimilar ↗
Alvotech Holdings S.A. has entered into a settlement agreement with AbbVie Inc (NYSE: ABBV), allowing Alvotech to market AVT02 (100 mg/mL), its high-... 
Via Benzinga
News headline image
Viatris's Return On Capital Employed Overview ↗
Benzinga Pro data, Viatris (NASDAQ:VTRS) reported Q4 sales of $4.34 billion. Earnings fell to a loss of $263.80 million, resulting in a 184.69% decrease from last quarter.... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022 ↗
Upgrades Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ:RVMD) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71,... 
Via Benzinga
News headline image
Why Viatris Shares Are Trading Lower Today ↗
Viatris Inc (NASDAQ: VTRS) is trading lower Monday after the company reported worse-than-expected top-line results for the fourth quarter and issued guidance... 
Via Benzinga
News headline image
67 Biggest Movers From Yesterday ↗
Gainers Mullen Automotive, Inc. (NASDAQ: MULN) climbed 145.6% to close at $1.69 on Monday after the company reported progress on solid-state polymer battery pack... 
Via Benzinga
< Previous 1 2
...
14 15 16 17 18 19 20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story